
                <!DOCTYPE html>
                <html lang="en">
                <head>
                    <meta charset="UTF-8">
                    <meta name="viewport" content="width=device-width, initial-scale=1.0">
                    <title>AAO 2024: New Horizons in the Treatment of Wet AMD</title>
                </head>
                <body>
                    <h1>AAO 2024: New Horizons in the Treatment of Wet AMD</h1>
                    <h2>Headings:</h2>
                    <h1>AAO 2024: New Horizons in the Treatment of Wet AMD</h1>
                    <h2>Paragraphs:</h2>
                    <p>Medscape</p><p>Univadis</p><p>Medscape</p><p>Univadis</p><p>No Results</p><p>No Results</p><p>Arshad M. Khanani, MD, MA</p><p>November 12, 2024</p><p>Arshad M. Khanani, MD, reflects on updates he has integrated into his practice following insights from the AAO 2024 annual meeting's retina subspecialty day. Dr Khanani highlights recent research on neovascular AMD, emphasizing Dr Barbara Blodi’s findings on macular atrophy and extending treatment intervals for stable patients.</p><p>Dr Khanani also discusses advancements in identifying fibrosis biomarkers, particularly via OCT imaging, and combination therapies for polypoidal choroidal vasculopathy (PCV). Dr Khanani concludes with his own groundbreaking AAO presentation on ABBV-RGX-314 gene therapy, which demonstrates substantial reduction in treatment needs and shows promise for bilateral dosing in patients with AMD.</p><p>Medscape © 2024 WebMD, LLC</p><p>Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.</p><p></p><p>Cite this: AAO 2024: New Horizons in the Treatment of Wet AMD -Medscape- Nov 12, 2024.</p><p>Clinical Professor, Department of Surgery, University of Nevada, Reno School of Medicine; Director of Clinical Research, Sierra Eye Associates, Reno, NevadaDisclosure: Arshad M. Khanani, MD, MA, has disclosed the following relevant financial relationships:Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Adverum; Alcon; Amgen; Annexin; Annexon; Apellis Pharmaceuticals; Aviceda Therapeutics; Beacon Therapeutics; Boehringer Ingelheim; Clearside Biomedical; Complement Therapeutics; 4DMT; Exegenesis; EyePoint Pharmaceuticals; Frontera Therapeutics; Genentech; Gyroscope Therapeutics; i-Lumen Scientific; Iveric Bio; Janssen Pharmaceuticals; Kodiak Sciences; Kriya Therapeutics; Nanoscope; Novartis; Ocular Therapeutix; Oculis; Ocuphire; OcuTerra; Olive BioPharma; Opthea; Oxular; Oxurion; Perfuse; Ray Therapeutics; Recens Medical; Regeneron Pharmaceuticals; Regenxbio; Revive; RevOpsis; Roche; Sanofi; Stealth BioTherapeutics; Thea Pharma; Unity BiotechnologyServe(d) as a speaker or a member of a speakers bureau for: Iveric Bio</p><p>You have already selectedfor My Alerts</p><p>Click the topic below to receive emails when new articles are available.</p><p>You've successfully addedto your alerts. You will receive email when new content is published.</p><p>processing....</p><p></p>
                </body>
                </html>
            